secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001104659-25-085976
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement
--------------------------------------------------------------------------------

- TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).
- Statistically significant improvements in secondary endpoints including time to first clinical worsening, K-BILD, and DLCO.
- Safety profile consistent with prior Tyvaso studies; no new safety signals observed.
- Company plans FDA meeting to discuss expedited review; TETON-1 data expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465925085976/0001104659-25-085976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465925085976/tm2524831d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-085976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer